Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for …
D Capodanno, RP Milluzzo… - Therapeutic Advances …, 2019 - journals.sagepub.com
Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or
stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In …
stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In …
Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention
M Vaduganathan, RA Harrington, GW Stone… - Journal of the American …, 2017 - jacc.org
Background Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in
patients undergoing percutaneous coronary intervention (PCI). Objectives This study sought …
patients undergoing percutaneous coronary intervention (PCI). Objectives This study sought …
Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory …
M Vaduganathan, RA Harrington, GW Stone… - JAMA …, 2017 - jamanetwork.com
Importance In the context of contemporary pharmacotherapy, optimal antiplatelet
management with percutaneous coronary intervention (PCI) has not been well established …
management with percutaneous coronary intervention (PCI) has not been well established …
Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary …
Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …
[HTML][HTML] Effect of platelet inhibition with cangrelor during PCI on ischemic events
Background The intensity of antiplatelet therapy during percutaneous coronary intervention
(PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a …
(PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a …
Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II …
AB Greenbaum, CL Grines, JA Bittl, RC Becker… - American heart …, 2006 - Elsevier
BACKGROUND: Platelet-initiated acute thrombosis and coronary embolization are
fundamental in the pathophysiology of complications during percutaneous coronary …
fundamental in the pathophysiology of complications during percutaneous coronary …
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
Background Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that
was tested for percutaneous coronary intervention (PCI) in three large, double-blind …
was tested for percutaneous coronary intervention (PCI) in three large, double-blind …
Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor Versus …
BACKGROUND: Cangrelor is an intravenous P2Y12 inhibitor approved to reduce
periprocedural ischemic events in patients undergoing percutaneous coronary intervention …
periprocedural ischemic events in patients undergoing percutaneous coronary intervention …
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
S Leonardi, KW Mahaffey, HD White, CM Gibson… - American heart …, 2012 - Elsevier
BACKGROUND: Despite robust efficacy in the reduction of ischemic events in patients who
require percutaneous coronary intervention (PCI), current P2Y12 inhibitors have limitations …
require percutaneous coronary intervention (PCI), current P2Y12 inhibitors have limitations …